The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Opioid-induced constipation: a narrative review of therapeutic options in clinical management

  • Received : 2018.08.24
  • Accepted : 2019.01.14
  • Published : 2019.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Pain therapy often entails gastrointestinal adverse events. While opioids are effective drugs for pain relief, the incidence of opioid-induced constipation (OIC) varies greatly from 15% to as high as 81%. This can lead to a significant impairment in quality of life, often resulting in discontinuation of opioid therapy. In this regard, a good doctor-patient relationship is especially pivotal when initiating opioid therapy. In addition to a detailed history of bowel habits, patient education regarding the possible gastrointestinal side effects of the drugs is crucial. In addition, the bowel function must be regularly evaluated for the entire duration of treatment with opioids. Furthermore, if the patient has preexisting constipation that is well under control, continuation of that treatment is important. In the absence of such history, general recommendations should include sufficient fluid intake, physical activity, and regular intake of dietary fiber. In patients of OIC with ongoing opioid therapy, the necessity of opioid use should be critically reevaluated in terms of an with acceptable quality of life, particularly in cases of non-cancer pain. If opioids must be continued, lowering the dose may help, as well as changing the type of opioid. If these measures do not suffice, the next step for persistent OIC is the administration of laxatives. If these are ineffective as well, treatment with peripherally active ${\mu}$-opioid receptor antagonists should be considered. Enemas and irrigation are emergency measures, often used as a last resort.

Keywords

References

  1. Hauser W, Bernardy K, Maier C. Long-term opioid therapy in chronic noncancer pain: a systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks. Schmerz 2015; 29: 96-108. https://doi.org/10.1007/s00482-014-1452-0
  2. Kalso E, E dwards JE, Moore RA, McQuay H J. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112: 372-80. https://doi.org/10.1016/j.pain.2004.09.019
  3. Sondergaard J, Christensen HN, Ibsen R, Jarbol DE, Kjellberg J. Healthcare resource use and costs of opioid-induced constipation among non-cancer and cancer patients on opioid therapy: a nationwide register-based cohort study in Denmark. Scand J Pain 2017; 15: 83-90. https://doi.org/10.1016/j.sjpain.2017.01.006
  4. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011; 106: 835-42. https://doi.org/10.1038/ajg.2011.30
  5. Ketw aroo GA, C heng V , Lembo A. O pioid-induced bow el dysfunction. Curr Gastroenterol Rep 2013; 15: 344. https://doi.org/10.1007/s11894-013-0344-2
  6. Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol 2015; 8: 206-20. https://doi.org/10.1177/1756283X15578608
  7. Tafelski S, Beutlhauser T, Bellin F, Reuter E, Fritzsche T, West C, et al. Incidence of constipation in patients with outpatient opioid therapy. Schmerz 2016; 30: 158-65. German. https://doi.org/10.1007/s00482-015-0018-0
  8. Gaertner J, Siemens W, Camilleri M, Davies A, Drossman DA, Webster LR, et al. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol 2015; 49: 9-16. https://doi.org/10.1097/MCG.0000000000000246
  9. Brenner DM, Stern E, Cash BD. Opioid-related constipation in patients with non-cancer pain syndromes: a review of evidence-based therapies and justification for a change in nomenclature. Curr Gastroenterol Rep 2017; 19: 12. https://doi.org/10.1007/s11894-017-0560-2
  10. Ducrotte P, Milce J, Soufflet C, Fabry C. Prevalence and clinical features of opioid-induced constipation in the general population: a French study of 15,000 individuals. United European Gastroenterol J 2017; 5: 588-600. https://doi.org/10.1177/2050640616659967
  11. Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, Galluzzi KE, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med 2015; 16: 2324-37. https://doi.org/10.1111/pme.12937
  12. Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999; 34: 870-7. https://doi.org/10.1080/003655299750025327
  13. Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005; 40: 540-51. https://doi.org/10.1080/00365520510012208
  14. Coyne KS, Currie BM, Holmes WC, Crawley JA. Assessment of a stool symptom screener and understanding the opioidinduced constipation symptom experience. Patient 2015; 8: 317-27. https://doi.org/10.1007/s40271-014-0087-7
  15. Rentz AM, van Hanswijck de Jonge P, Leyendecker P, Hopp M. Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries. Curr Med Res Opin 2011; 27: 35-44.
  16. Camilleri M, Rothman M, Ho KF, Etropolski M. Validation of a bowel function diary for assessing opioid-induced constipation. Am J Gastroenterol 2011; 106: 497-506. https://doi.org/10.1038/ajg.2010.431
  17. Sobczak M, Salaga M, Storr MA, Fichna J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol 2014; 49: 24-45. https://doi.org/10.1007/s00535-013-0753-x
  18. Brock C, Olesen SS, Olesen AE, Frokjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012; 72: 1847-65. https://doi.org/10.2165/11634970-000000000-00000
  19. Dorn S, Lembo A, Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Am J Gastroenterol Suppl 2014; 2: 31-7. https://doi.org/10.1038/ajgsup.2014.7
  20. Galligan JJ, Burks TF. Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat. J Pharmacol Exp Ther 1983; 226: 356-61.
  21. Finco G, Pintor M, Sanna D, Orru G, Musu M, De Conno F, et al. Is target opioid therapy within sight? Minerva Anestesiol 2012; 78: 462-72.
  22. Vallerand AH, Hendry S, Baldys E, Hu Y, Datto C. Analysis of patient-provider interactions regarding the burden and treatment of opioid-induced constipation in adults with chronic noncancer pain. Pain Med 2018 Aug 13 [Epub]. Available at https://doi.org/10.1093/pm/pny151.
  23. Muller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100: 232-42. https://doi.org/10.1111/j.1572-0241.2005.40885.x
  24. De Schryver AM, Keulemans YC, Peters HP, Akkermans LM, Smout AJ, De Vries WR, et al. Effects of regular physical activity on defecation pattern in middle-aged patients complaining of chronic constipation. Scand J Gastroenterol 2005; 40: 422-9. https://doi.org/10.1080/00365520510011641
  25. Andresen V, Enck P, Frieling T, Herold A, Ilgenstein P, Jesse N, et al. S2k guideline for chronic constipation: definition, pathophysiology, diagnosis and therapy. Z Gastroenterol 2013; 51: 651-72. https://doi.org/10.1055/s-0033-1335808
  26. Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther 2011; 33: 895-901. https://doi.org/10.1111/j.1365-2036.2011.04602.x
  27. Ruston T, Hunter K, Cummings G, Lazarescu A. Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation: a systematic review. Can Oncol Nurs J 2013; 23: 236-46. https://doi.org/10.5737/1181912x234236240
  28. Rauck RL, Hong KJ, North J. Opioid-induced constipation survey in patients with chronic noncancer pain. Pain Pract 2017; 17: 329-35. https://doi.org/10.1111/papr.12445
  29. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: e58-68. https://doi.org/10.1016/S1470-2045(12)70040-2
  30. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2--guidance. Pain Physician 2012; 15(3 Suppl): S67-116.
  31. Freedman MD, Schwartz HJ, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol 1997; 37: 904-7. https://doi.org/10.1002/j.1552-4604.1997.tb04264.x
  32. Muller-Lissner S. Myth about causes and treatment of constipation. MMW Fortschr Med 2013; 155: 56-7. https://doi.org/10.1007/s15006-013-2517-1
  33. Leppert W. Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Des Devel Ther 2015; 9: 2215-31. https://doi.org/10.2147/DDDT.S32684
  34. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009; 38: 426-39. https://doi.org/10.1016/j.jpainsymman.2009.06.001
  35. Michaeli K, Liebhauser M, Bornemann-Cimenti H, Wejbora M, Sandner-Kiesling A. Opioid dose ratios in pain therapy: an evidence-based contemplation. Eur J Anaesthesiol 2010; 27: 25-6.
  36. Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, Mangione S. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009; 37: 632-41. https://doi.org/10.1016/j.jpainsymman.2007.12.024
  37. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine (Phila Pa 1976) 2005; 30: 2484-90. https://doi.org/10.1097/01.brs.0000186860.23078.a8
  38. Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 2008; 11: 492-501. https://doi.org/10.1089/jpm.2007.0200
  39. Ahn JS, Lin J, Ogawa S, Yuan C, O'Brien T, Le BH, et al. Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. J Pain Res 2017; 10: 1963-72. https://doi.org/10.2147/JPR.S140320
  40. Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev 2013; (10): CD010270.
  41. Chang EJ, Choi EJ, Kim KH. Tapentadol: can it kill two birds with one stone without breaking windows? Korean J Pain 2016; 29: 153-7. https://doi.org/10.3344/kjp.2016.29.3.153
  42. Tzschentke TM, Christoph T, Kogel B, Schiene K, Hennies HH, Englberger W, et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007; 323: 265-76. https://doi.org/10.1124/jpet.107.126052
  43. Mercadante S. The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review. Curr Med Res Opin 2017; 33: 1965-9. https://doi.org/10.1080/03007995.2017.1379981
  44. Lange B, von Zabern D, Elling C, Dubois C. Efficacy and safety of tapentadol prolonged release for moderateto-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies. Curr Med Res Opin 2017; 33: 1413-22. https://doi.org/10.1080/03007995.2017.1335188
  45. Xiao JP, Li AL, Feng BM, Ye Y, Wang GJ. Efficacy and safety of tapentadol immediate release assessment in treatment of moderate to severe pain: a systematic review and metaanalysis. Pain Med 2017; 18: 14-24. https://doi.org/10.1093/pm/pnw154
  46. Leppert W. Oxycodone/naloxone in the management of patients w ith pain a nd o pioid-induced bow el d ysfunction. Curr Drug Targets 2014; 15: 124-35. https://doi.org/10.2174/13894501113149990210
  47. Bujedo BM. Treatment of failed back surgery syndrome in a forty-three-year-old man with high-dose oxycodone/naloxone. Anesth Pain Med 2015; 5: e21009.
  48. Koopmans G, Simpson K, De Andres J, Lux EA, Wagemans M, Van Megen Y. Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives. Curr Med Res Opin 2014; 30: 2389-96 https://doi.org/10.1185/03007995.2014.971355
  49. Morlion BJ, Mueller-Lissner SA, Vellucci R, Leppert W, Coffin BC, Dickerson SL, et al. Oral prolonged-release oxycodone/naloxone for managing pain and opioid-induced constipation: a review of the evidence. Pain Pract 2018; 18: 647-65. https://doi.org/10.1111/papr.12646
  50. Rychlik R, Viehmann K, Daniel D, Kiencke P, Kresimon J. Pain management and costs of a combination of oxycodone+ naloxone in low back pain patients. In: Pain management- current issues and opinions. Edited by Racz G. Rijeka, Intech. 2012, pp 307-20.
  51. Ueberall MA, Mueller-Schwefe GH. Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations. J Pain Res 2016; 9: 1001-20. https://doi.org/10.2147/JPR.S112418
  52. Poulsen JL, Brock C, Gronlund D, Liao D, Gregersen H, Krogh K, et al. Prolonged-release oxycodone/naloxone improves anal sphincter relaxation compared to oxycodone plus macrogol 3350. Dig Dis Sci 2017; 62: 3156-66. https://doi.org/10.1007/s10620-017-4784-7
  53. Fruhwald S, Holzer P, Metzler H. Gastrointestinal motility in acute illness. Wien Klin Wochenschr 2008; 120: 6-17. https://doi.org/10.1007/s00508-007-0920-2
  54. Papa P, Turconi L. Neostigmine for the treatment of gastrointestinal atony: a report of one case. J Palliat Med 2011; 14: 1270-3. https://doi.org/10.1089/jpm.2010.0390
  55. Klivinyi C, Bornemann-Cimenti H. Pain medication and long QT syndrome. Korean J Pain 2018; 31: 3-9. https://doi.org/10.3344/kjp.2018.31.1.3
  56. Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol 2007; 554: 98-105. https://doi.org/10.1016/j.ejphar.2006.10.019
  57. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioidinduced constipation: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 1566-74; quiz 1575. https://doi.org/10.1038/ajg.2013.169
  58. Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010; 55: 2912-21. https://doi.org/10.1007/s10620-010-1229-y
  59. Holder RM, Rhee D. Novel oral therapies for opioid-induced bowel dysfunction in patients with chronic noncancer pain. Pharmacotherapy 2016; 36: 287-99. https://doi.org/10.1002/phar.1711
  60. Cuppoletti J, Chakrabarti J, Tewari K, Malinowska DH. Methadone but not morphine inhibits lubiprostone-stimulated Cl- currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl- currents. Cell Biochem Biophys 2013; 66: 53-63. https://doi.org/10.1007/s12013-012-9406-6
  61. Jamal MM, Adams AB, Jansen JP, Webster LR. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol 2015; 110: 725-32. https://doi.org/10.1038/ajg.2015.106
  62. Cryer B, Katz S, Vallejo R, Popescu A, Ueno R. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2014; 15: 1825-34. https://doi.org/10.1111/pme.12437
  63. Spierings EL, Drossman DA, Cryer B, Mazen Jamal M, Losch-Beridon T, Mareya SM, et al. Efficacy and safety of lubiprostone in patients with opioid-induced constipation: phase 3 study results and pooled analysis of the effect of concomitant methadone use on clinical outcomes. Pain Med 2018; 19: 1184-94. https://doi.org/10.1093/pm/pnx156
  64. Zacny JP, Wroblewski K, Coalson DW. Methylnaltrexone: its pharmacological effects alone and effects on morphine in healthy volunteers. Psychopharmacology (Berl) 2015; 232: 63-73. https://doi.org/10.1007/s00213-014-3637-8
  65. Sridharan K, Sivaramakrishnan G. Drugs for treating opioid-induced constipation: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials. J Pain Symptom Manage 2018; 55: 468-479.e1. https://doi.org/10.1016/j.jpainsymman.2017.08.022
  66. Jagla C, Martus P, Stein C. Peripheral opioid receptor blockade increases postoperative morphine demands: a randomized, double-blind, placebo-controlled trial. Pain 2014; 155: 2056-62. https://doi.org/10.1016/j.pain.2014.07.011
  67. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014; 370: 2387-96. https://doi.org/10.1056/NEJMoa1310246
  68. Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebocontrolled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioidinduced constipation. Pain 2013; 154: 1542-50. https://doi.org/10.1016/j.pain.2013.04.024
  69. Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. J Palliat Med 2015; 18: 593-600. https://doi.org/10.1089/jpm.2014.0362
  70. Nalamachu S, Gudin J, Datto C, Coyne K, Poon JL, Hu Y. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use. J Opioid Manag 2018; 14: 211-21. https://doi.org/10.5055/jom.2018.0451
  71. Irving G, Penzes J, Ramjattan B, Cousins M, Rauck R, Spierings EL, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioidinduced bowel dysfunction in patients with non-cancer pain. J Pain 2011; 12: 175-84. https://doi.org/10.1016/j.jpain.2010.06.013
  72. Jansen JP, Lorch D, Langan J, Lasko B, Hermanns K, Kleoudis CS, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioidinduced bowel dysfunction in patients with non-cancer pain. J Pain 2011; 12: 185-93. https://doi.org/10.1016/j.jpain.2010.06.012
  73. Gyawali B, Hayashi N, Tsukuura H, Honda K, Shimokata T, Ando Y. Opioid-induced constipation. Scand J Gastroenterol 2015; 50: 1331-8. https://doi.org/10.3109/00365521.2015.1054423
  74. Markham A. Naldemedine: first global approval. Drugs 2017; 77: 923-7. https://doi.org/10.1007/s40265-017-0750-0
  75. Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol 2017; 2: 555-64. https://doi.org/10.1016/S2468-1253(17)30105-X
  76. Webster LR, Yamada T, Arjona Ferreira JC. A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2017; 18: 2350-60. https://doi.org/10.1093/pm/pnw325
  77. Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, et al. Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol 2017; 35: 3859-66. https://doi.org/10.1200/JCO.2017.73.0853
  78. Katakami N, Oda K, Tauchi K, Nakata K, Shinozaki K, Yokota T, et al. Phase IIb, randomized, double-blind, placebocontrolled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer. J Clin Oncol 2017; 35: 1921-8. https://doi.org/10.1200/JCO.2016.70.8453
  79. Murphy JA, Sheridan EA. Evidence based review of pharmacotherapy for opioid-induced constipation in noncancer pain. Ann Pharmacother 2018; 52: 370-9. https://doi.org/10.1177/1060028017739637
  80. Bove A, Bellini M, Battaglia E, Bocchini R, Gambaccini D, Bove V, et al. Consensus statement AIGO/SICCR diagnosis and treatment of chronic constipation and obstructed defecation (part II: treatment). World J Gastroenterol 2012; 18: 4994-5013. https://doi.org/10.3748/wjg.v18.i36.4994
  81. Muller-Lissner S, Bassotti G, Coffin B, Drewes AM, Breivik H, Eisenberg E, et al. Opioid-induced constipation and bowel dysfunction: a clinical guideline. Pain Med 2017; 18: 1837-63.
  82. Drewes AM, Munkholm P, Simren M, Breivik H, Kongsgaard UE, Hatlebakk JG, et al. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. Scand J Pain 2016; 11: 111-22. https://doi.org/10.1016/j.sjpain.2015.12.005

Cited by

  1. Opioid: toward an effective strategy for better use vol.32, pp.2, 2019, https://doi.org/10.3344/kjp.2019.32.2.67
  2. Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel vol.38, pp.7, 2019, https://doi.org/10.1007/s12325-021-01766-y